甘李药业: 关于使用闲置募集资金进行现金管理到期赎回的公告

Core Viewpoint - 甘李药业股份有限公司 has approved the continued use of idle raised funds for cash management, allowing for the investment of up to 250 million RMB in safe and liquid financial products while ensuring that it does not affect the planned use of raised funds for investment projects [2]. Group 1: Cash Management Approval - The company’s board and supervisory board have approved the proposal to use idle raised funds for cash management, with a focus on safety and liquidity [2]. - The maximum amount for investment is set at 250 million RMB, with a duration of up to 12 months from the date of board approval [2]. - The investment products include fixed deposits, structured deposits, and other low-risk financial instruments, which cannot be used for pledging or securities investment purposes [2]. Group 2: Redemption of Financial Products - The company has redeemed a total of 200 million RMB in principal from its financial products, along with an interest income of 2.1819 million RMB, which aligns with expected returns [2]. - The financial products involved were structured deposits, with the principal and earnings transferred to the dedicated account for raised funds [2]. Group 3: Recent Financial Management Overview - In the past 12 months, the company has invested a total of 400 million RMB in financial products, with a total return of 4.9189 million RMB [4]. - The highest single-day investment amount in the last 12 months was 200 million RMB, representing a certain percentage of the company's net assets [5]. - The total available investment limit for financial management is 250 million RMB, with 25 million RMB remaining unused [5].